BB Biotech (Switzerland) Performance
| BION Stock | CHF 37.30 0.25 0.67% |
The firm owns a Beta (Systematic Risk) of 0.54, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BB Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding BB Biotech is expected to be smaller as well. At this point, BB Biotech AG has a negative expected return of -4.0E-4%. Please make sure to confirm BB Biotech's market risk adjusted performance, coefficient of variation, jensen alpha, as well as the relationship between the mean deviation and standard deviation , to decide if BB Biotech AG performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BB Biotech AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, BB Biotech is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 6.8 M |
BION |
BB Biotech Relative Risk vs. Return Landscape
If you would invest 3,750 in BB Biotech AG on September 5, 2024 and sell it today you would lose (20.00) from holding BB Biotech AG or give up 0.53% of portfolio value over 90 days. BB Biotech AG is generating negative expected returns and assumes 1.261% volatility on return distribution over the 90 days horizon. Simply put, 11% of stocks are less volatile than BION, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BB Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BB Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BB Biotech AG, and traders can use it to determine the average amount a BB Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -3.0E-4
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BION |
Estimated Market Risk
| 1.26 actual daily | 11 89% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BB Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BB Biotech by adding BB Biotech to a well-diversified portfolio.
BB Biotech Fundamentals Growth
BION Stock prices reflect investors' perceptions of the future prospects and financial health of BB Biotech, and BB Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BION Stock performance.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.0411 | |||
| Operating Margin | 1.25 % | |||
| Current Valuation | 509.23 M | |||
| Shares Outstanding | 54.99 M | |||
| Price To Earning | 23.12 X | |||
| Price To Book | 1.28 X | |||
| Price To Sales | 814,184 X | |||
| Revenue | (396.22 M) | |||
| EBITDA | (403.75 M) | |||
| Cash And Equivalents | 2.83 M | |||
| Cash Per Share | 65.76 X | |||
| Debt To Equity | 11.30 % | |||
| Book Value Per Share | 49.62 X | |||
| Cash Flow From Operations | (94.79 M) | |||
| Earnings Per Share | (16.73) X | |||
| Total Asset | 3.64 B | |||
About BB Biotech Performance
Evaluating BB Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BB Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BB Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland. BB BIOTECH operates under Pharmaceuticals And Biosciences classification in Switzerland and is traded on Switzerland Exchange.Things to note about BB Biotech AG performance evaluation
Checking the ongoing alerts about BB Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BB Biotech AG help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BB Biotech AG generated a negative expected return over the last 90 days | |
| BB Biotech AG has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (404.81 M) with profit before overhead, payroll, taxes, and interest of 4 K. | |
| BB Biotech AG has accumulated about 2.83 M in cash with (94.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 65.76, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing BB Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BB Biotech's stock is overvalued or undervalued compared to its peers.
- Examining BB Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BB Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BB Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BB Biotech's stock. These opinions can provide insight into BB Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BION Stock Analysis
When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.